Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | glutathione reductase, putative | 0.0051 | 0.2727 | 1 |
Schistosoma mansoni | dihydrolipoamide dehydrogenase | 0.0018 | 0.0556 | 0.0556 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0116 | 0.6983 | 0.892 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0018 | 0.0556 | 1 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0018 | 0.0556 | 1 |
Leishmania major | trypanothione reductase | 0.0051 | 0.2727 | 1 |
Mycobacterium leprae | PROBABLE NADH DEHYDROGENASE NDH | 0.0116 | 0.6983 | 0.892 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0129 | 0.7793 | 1 |
Echinococcus granulosus | dihydrolipoamide dehydrogenase | 0.0018 | 0.0556 | 0.2038 |
Plasmodium falciparum | glutathione reductase | 0.0051 | 0.2727 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0129 | 0.7793 | 1 |
Treponema pallidum | NADH oxidase | 0.0018 | 0.0556 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0051 | 0.2727 | 1 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0051 | 0.2727 | 0.3483 |
Plasmodium falciparum | thioredoxin reductase | 0.0051 | 0.2727 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0018 | 0.0556 | 0.5 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0018 | 0.0556 | 1 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0018 | 0.0556 | 0.5 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0116 | 0.6983 | 0.892 |
Echinococcus multilocularis | dihydrolipoamide dehydrogenase | 0.0018 | 0.0556 | 0.2038 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0018 | 0.0556 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0051 | 0.2727 | 1 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0129 | 0.7829 | 1 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0018 | 0.0556 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0051 | 0.2727 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0018 | 0.0556 | 1 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0116 | 0.6983 | 0.892 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0018 | 0.0556 | 1 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0051 | 0.2727 | 1 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0116 | 0.6983 | 0.892 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0051 | 0.2727 | 1 |
Mycobacterium tuberculosis | Probable soluble pyridine nucleotide transhydrogenase SthA (STH) (NAD(P)(+) transhydrogenase [B-specific]) (nicotinamide nucleot | 0.0018 | 0.0556 | 0.071 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0129 | 0.7829 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0051 | 0.2727 | 0.3284 |
Brugia malayi | glutathione reductase | 0.0051 | 0.2727 | 0.3284 |
Trypanosoma brucei | trypanothione reductase | 0.0051 | 0.2727 | 1 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0018 | 0.0556 | 0.0405 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0129 | 0.7793 | 1 |
Mycobacterium tuberculosis | Probable reductase | 0.0116 | 0.6983 | 0.892 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0129 | 0.7829 | 1 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0129 | 0.7829 | 1 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0116 | 0.6983 | 0.892 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.